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Abstract: Oxidative stress, inflammation and androgen receptor (AR) signaling play a pivotal role
in the initiation, development and progression of prostate cancer (PCa). Numerous papers in
the literature have documented the interconnection between oxidative stress and inflammation;
and how antioxidants can combat the inflammation. It has been shown in the literature that both
oxidative stress and inflammation regulate AR, the key receptor involved in the transition of PCa
to castration resistant prostate cancer (CRPC). In this review, we discuss about the importance
of targeting Nrf-2-antioxidant signaling, NF-κB inflammatory response and AR signaling in PCa.
Finally, we discuss about the crosstalk between these three critical pathways as well as how
the anti-inflammatory antioxidant phytochemicals like sulforaphane (SFN) and curcumin (CUR),
which can also target AR, can be ideal candidates in the chemoprevention of PCa.
Keywords: prostate cancer; castration resistant prostate cancer (CRPC); oxidative stress; inflammation;
androgen receptor (AR); AR-V7; Nrf-2; NF-κB; sulforaphane; curcumin and bardoxolone methyl
1. Oxidative Stress and Prostate Cancer
Prostate cancer (PCa) is the second major cause of cancer in men and fifth leading cause of
cancer-associated deaths in men worldwide [1]. Numerous studies have underscored the connection
between oxidative stress and risk of developing prostate cancer [2,3]. Oxidative stress is characterized
by an imbalance between the production of reactive oxygen species (ROS) and the capability of
biological system to counterbalance the effects of reactive free radicals or restore oxidative damage [4].
High levels of ROS can also cause significant reduction in the antioxidant defense mechanisms resulting
in DNA, protein and lipid damage [5]. The oxidative damage may be aggravated by the reduced
efficacy of antioxidant defense mechanisms [6]. Hydroxyl radicals, peroxides and superoxides are
ROS that can be either generated through mitochondria or extra mitochondrial NAD(P)H oxidase
(Nox) system [7,8]. Oxidative stress has been shown to contribute to the initiation and progression of
PCa by regulating transcription factors, cell cycle regulators and DNA [9,10]. Chronic increase in the
levels of ROS causes somatic mutations as well as neoplastic transformations [11]. Antioxidant therapy
may prevent PCa by combating oxidative stress [12]. Intrinsic oxidative stress can have an effect on
various functions in cancer cells such as cellular proliferation, genetic instability and advancement
of mutations, changes in sensitivity of the cells to anticancer agents, invasion and metastasis [13,14].
Optimal levels of intracellular ROS are critical in maintaining cellular signaling and homeostatic redox
balance. Most importantly, the real effects of oxidative stress are contingent upon the genetics of the
cell, the kind of ROS involved and also the duration and levels of ROS [15,16]. Oxidative stress is
inherent in PCa cells and is vital for aggressive phenotype [5]. Numerous factors linked with PCa
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like aging, antioxidant system, androgen imbalance, dietary fat and premalignant conditions may be
associated with oxidative stress [17].
In response to oxidative stress, there is an activation of nuclear factor erythroid 2 -like 2
(NFE2L2; more commonly known as Nrf-2)/Kelch-like erythroid cell-derived protein with CNC
homology-associated protein 1, (Keap1)signaling pathway [18]. Nrf-2 is a transcription factor
regulating the basal as well as inducible expression of numerous antioxidant and detoxification
enzymes [19]. Nrf-2 signaling along with other interacting and regulatory proteins and molecules is
certainly the most vital defense and survival pathway employed by cells against oxidative stress [20].
Nrf-2 is normally present in the cytoplasm bound to repressor protein Keap1 which promotes its
degradation by ubiquitin proteasome pathway (Figure 1).
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and vice versa. Oxidative stress results in the activation and nuclear localization of rf-2 after its
dissociation from Keap1. Nrf-2 after localizing to the nucleus binds to the antioxidant response elements
leading to the transcription and translation of antioxidant proteins. Inflammation, on the other hand,
leads to the activation and nuclear localization of NF-κB after its dissociation from IκB, where it binds
to NF-κB response elements leading to the transcription and translation of inflammatory proteins. Nrf2
signaling inhibits NF-κB signaling nd vice versa. On the other hand, Nrf-2 inhibits AR whereas NF-κB
activates AR signaling. AR after binding to androgens dissociat s from HSPs (heat shock proteins),
t anslocates to the nucleus leadi g to the transcription and translation of AR regulated pro ei s like
prostate specific antigen (PSA).
Electrophiles (under stress conditions) alter the cysteine residues of eap1 resulting in the
revention of ubiquitination of Nrf-2 [21]. Nrf-2 thus translocates to the nucleus where it
along with the small Maf proteins binds to the antioxidant response elements present in the
promoter region of target genes. This leads to the transcription and translation of antioxidant
enzymes/phase II detoxifying enzymes incl ding NAD(P)H:quinone oxidoreductase-1 (NQO-1),
heme-oxygenase-1(HO-1), glutathione S-transferaseA2 (GSTA2), γ-glutamylcysteine synthetase
(GCS), epoxide hydrolase, leukotriene B4 dehydrogenase, aflatoxin B1 dehydrogenase, ferritin and
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UDP-glucuronosyltransferase (UGT) 1A1 [22–24] (Table 1). Disturbance in Nrf-2 signaling are
likely to enhance predisposition to oxidative damage and toxicants in humans and various model
organisms [25–29]. Mice deficient in Nrf-2 were extremely more susceptible to carcinogens and showed
augmented lung metastasis along with elevated ROS levels [30,31]. The prevalence, multiplicity and
size of colorectal tumors was reported to increase in Nrf-2 knock out mice [32]. Several studies have
reported the cancer chemopreventive effect of Nrf-2 activation [33,34]. During the progression of
PCa in transgenic adenocarcinoma of the mouse prostate (TRAMP) mice, constant downregulation of
Nrf-2 and its downstream target genes was reported [35]. Nrf-2 has been shown to suppress growth
and migration of PCa cells by upregulating ferroportin [36] and sensitize PCa cells to radiation by
reducing basal ROS levels [37]. Chemoprevention by phytochemicals like sulforaphane (SFN) [38–42]
and curcumin (CUR) [43–47] has been attributed to the activation of Nrf-2 pathway.
Table 1. Downstream target genes of Nrf-2, NF-κB and AR.
Downstream Target Genes
Nrf-2
NAD(P)H:quinone oxidoreductase-1 (NQO-1), heme-oxygenase-1 (HO-1), glutathione S-transferaseA2
(GSTA2), γ-glutamylcysteine synthetase (GCS), epoxide hydrolase, leukotriene B4 dehydrogenase,
aflatoxin B1 dehydrogenase, ferritin and UDP-glucuronosyltransferase (UGT) 1A1
NF-κB
Caspase-8 inhibitor FLIP, the inhibitor of apoptosis proteins c-IAP1/2 and XIAP, B-cell lymphoma 2
(Bcl-2), Bcl-extralarge (Bcl-xL), Bax (bcl-2-like protein 4), vascular-endothelial growth factor (VEGF),
basic fibroblast growth factor (bFGF), IL-8, matrix metalloproteinase-9 (MMP-9), selectins and integrins
AR
Prostate specific antigen (PSA), fibroblast growth factor 8 (FGF8), cyclin dependent kinase 1 (Cdk1),
Cdk2, prostate transmembrane protein androgen induced 1 (PMEPA1), transmembrane serine protease
2 (TMPRSS2) and FK506 binding protein 5 (FKBP5)
2. Inflammation and Prostate Cancer
It has been a well-studied fact that chronic inflammation leads to the initiation and advancement of
PCa by modifying the tumor microenvironment altering the balance of chemokines, cytokines, ROS and
other transcriptional factors [48,49]. The extracellular matrix is remodeled which commences epithelial
mesenchymal transition (EMT). The constitutively active stroma formed promotes growth of the tumor
and metastatic phenotype [50]. Chronic inflammation in the specimens of benign prostate biopsy has
been linked with prostate tumors of high grade in the adjoining areas [51]. In prostatic intraepithelial
neoplasia (PIN) and PCa, there is a strong correlation of inflammation with proliferative inflammatory
atrophy (PIA) or “risk factor” lesions comprising of activated inflammatory and proliferating epithelial
cells [52].
A multitude of inflammatory cytokines have been shown to actively mediate between prostate
inflammation and PCa [53]. The expression of circulating macrophage inhibitory cytokine 1 (MIC-1)
was found to be augmented in PCa [54,55] and was associated with poor prognosis [56]. MIC-1
belongs to the superfamily of transforming growth factor-β (TGF-β) and has been advocated as a chief
link between macrophages and PCa [57]. Interleukin 6 (IL-6) is another important cytokine whose
expression has been found to increase in PCa [58]. It is secreted by macrophages, T lymphocytes and
endothelial cells and is implicated in various innate and adaptive inflammatory responses such as
thrombopoiesis, activation of B cells and acute-phase inflammatory response. IL-6 and IL6-receptor
(IL-6R) have been also shown to be synthesized by prostate cells and their expression has been found
to be upregulated in high-grade PIN and malignant epithelium [59]. The circulating levels of IL-6
were found to be augmented in castration resistant and metastatic PCa [60] with poor prognosis [61].
Interestingly, IL-6 can also play a role in activating androgen receptor (AR) [62]. Also, it was reported
that a positive feedback loop between inflammation and activation of IL-6, signal transducer and
activator of transcription 3 (STAT3) and nuclear factor kappa-light-chain-enhancer of activated B cells
(NF-κB) retain cells in the state of epigenetic transformation [63].
NF-κB has emerged as a crucial link between inflammation and cancer [64]. The dimers of NF-κB
are found to be sequestered in the cytoplasm in unstimulated cells by inhibitor of κB (IκB) through
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ankyrin repeat domains (Figure 1). These domains hide the nuclear localization signals (NLS) of NF-κB
proteins preventing their translocation into the nucleus and thus activation [65]. NF-κB can be activated
by ROS, IL-1β, tumor necrosis factor alpha (TNFα), bacterial lipopolysaccharides (LPS) and ionizing
radiation. Upon activation, NF-κB translocates into the nucleus and binds to response elements on
DNA leading to the transcription and translation of its target genes. Among the specific target genes
of NF-κB involved in cancer, the major ones are caspase-8 inhibitor FLIP, the inhibitor of apoptosis
proteins c-IAP1/2 and XIAP, B-cell lymphoma 2 (Bcl-2), Bcl-extralarge (Bcl-xL), Bax (bcl-2-like protein
4), vascular-endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), IL-8, matrix
metalloproteinase-9 (MMP-9), selectins and integrins [66] (Table 1). Thus, NF-κB signaling is involved
in tumorigenesis by inducing cellular proliferation, suppressing apoptosis and supporting metastasis
and angiogenesis [67].
It has been reported that NF-κB mediated inflammation is even crucial in cancers whose growth
is not linked with primary inflammatory condition [68,69]. In PCa, inflammation, besides being part of
tumor progression, can also be elevated due to androgen deprivation therapy (ADT) mediated death
of the tumor [64]. NF-κB was shown to be constitutively active in PCa [70] and the active subunit
of NF-κB, p65 was found to be overexpressed in PIN as well as cancerous lesions [71]. Studies have
reported that AR activity is reduced by blocking NF-κB signaling in vitro [72,73]. Another study
showed that while activating NF-κB signaling did not form prostatic tumor, it did increase the rate
of progression of tumor in Hi-Myc mouse PCa model [74]. It has been also shown that by blocking
NF-κB signaling in PCa cells, invasion, angiogenesis and metastasis can be inhibited [75]. Interestingly,
one of the studies showed that sensitivity of CRPC cells to AR antagonists can be restored by targeting
NF-κB signaling using artesunate [76]. Another study showed that chemosensitivity to trichostatin A
was increased in Ki-Ras-transformed human prostate epithelial cells by inhibiting NF-κB and thus this
can be applied in anticancer therapy in PCa tumorigenic cells overexpressing Ki-Ras [77]. Also, NF-κB
signaling activation has been shown to promote growth of PCa cells in bone [78]. The translocation
of NF-κB into the nucleus was found to be upregulated in PCa lymph node metastasis [79]. Nuclear
translocation of NF-κB/p65 was shown to be an independent predictive factor of biochemical relapse
in PCa and also responsible for the transition from PIN to PCa [80]. Different NF-κB pathways and
dimers were proposed to be activated in the progression of PCa based on the nuclear translocation of
both canonical (RelA/p50) and non-canonical (RelB/p52) NF-κB subunits [81]. NF-κB was shown to
activate transcription regulatory element of prostate specific antigen (PSA) gene and NF-κB binding
sites were shown to be located in the PSA core enhancer [82]. The constitutive NF-κB binding activity
was reported to be higher in androgen independent PCa xenografts compared to androgen-dependent
PCa xenografts. These studies highlight the importance of targeting NF-κB both for the prevention
(transition of healthy cells to PIN or transition from PIN to cancer) as well as the treatment for PCa.
3. Androgen Receptor Signaling and Prostate Cancer
Androgen receptor (AR) signaling is indispensable for the development of prostate gland [83].
It is not only responsible for the initiation of PCa but also for the progression and transition to
castration resistant prostate cancer (CRPC) [84]. AR thus remains the primary therapeutic target in
PCa [85]. AR consists of three major functional domains: the N-terminal domain (NTD), DNA binding
domain (DBD) and C-terminal ligand binding domain (LBD). DBD is responsible for the binding
of AR to androgen response elements located in the promoter region of AR dependent genes like
PSA. In the absence of androgen, AR is found in the cytoplasm bound to its heat shock chaperone
proteins [86] (Figure 1). When androgens bind to AR, a conformational change is induced in AR leading
to dissociation of chaperone proteins and exposure of nuclear localization signal (NLS) responsible
for the nuclear translocation of AR. AR then dimerizes and binds to androgen response elements
resulting in the transcription and translation of the target genes. Among the specific target genes of
AR involved in PCa progression, the most important ones are PSA [87], fibroblast growth factor 8
(FGF8) [88], cyclin dependent kinase 1 (Cdk1), Cdk2 [89], prostate transmembrane protein androgen
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induced 1 (PMEPA1) [90], transmembrane serine protease 2 (TMPRSS2) [91] and FK506 binding protein
5 (FKBP5) [92] (Table 1). Androgen deprivation therapy (ADT) using luteinizing hormone releasing
hormone analogues or AR antagonists like bicalutamide, enzalutamide and flutamide so far remains the
gold standard treatment for PCa patients. Although almost all patients respond to ADT initially, PCa
eventually becomes resistant, leading to CRPC [93]. The major factors responsible for the development
of CRPC include intratumoral/intracrine production of androgens, AR co-activators overexpression,
AR gene amplification, ligand-independent activation of AR by cytokines or kinases [94–96] and the
expression of constitutively active AR variants (AR-Vs) lacking LBD, the major one being AR-V7 [97,98].
The crosstalk between AR and other signaling pathways in PCa modulates the transactivational
activity of AR. When AR function becomes dysregulated in PCa, it results in anomalous expression
of AR-dependent genes including transcription factors, cell cycle regulators and proteins critical
for cell survival, secretion and lipogenesis [96]. Randomized phase III studies have confirmed
that AR targeting either directly or by inhibiting androgen synthesis can significantly improve the
survival of metastatic CRPC patients [99]. Increased survival in PCa patients has been observed with
enzalutamide [100] and abiraterone acetate [101]. Novel therapeutic approaches using agents that can
directly target AR as well as siRNAs or non-coding RNAs are being developed to inhibit the growth of
CRPC [102]. AR-Vs play a major role not only in the progression of CRPC and loss of sensitivity to AR
targeting therapies like enzalutamide and abiraterone [103] but also in metastasis [104].
AR-V7 has been reported to be an imperative prognostic biomarker in CRPC [105,106]. AR-Vs
activate AR-FL in facilitating resistance to ADT [97]. The study showed that enzalutamide could more
potently prevent the growth of 22Rv1 xenograft tumors after knock down of AR-V7 highlighting the
importance of targeting both AR-FL and AR-Vs for completely abrogating AR signaling. Therapeutic
agents that can also target AR-Vs along with AR-FL are being currently developed to improve the
therapeutic efficacy in CRPC patients [107]. We recently showed that sulforaphane (SFN) can increase
the efficacy of antiandrogens like bicalutamide and enzalutamide by degrading AR in androgen
dependent as well as androgen independent PCa cells [108]. We also showed that SFN can increase the
efficacy of enzalutamide in enzalutamide resistant PCa cell line by degrading both AR-FL as well as
AR-V7 [109].
4. Interplay between Nrf-2-Antioxidant, NF-κB Inflammatory and AR Signaling
Nrf-2, NF-κB and AR signaling have emerged as the most crucial signaling pathways in PCa.
The interconnection between these three signaling pathways is involved in the initiation, development
and progression of PCa.
4.1. Crosstalk between Nrf-2 and NF-κB Signaling
Nrf2 and NF-κB in addition to individually affecting several signaling pathways for maintaining
a redox homeostasis also crosstalk with each other to further alter the levels of vital redox modulators
in both normal and disease conditions [110]. Antitumor effect mediated by Nrf-2 is attained by
both activation of antioxidant machinery as well as inhibition of NF-κB mediated pro-inflammatory
pathways [111]. Oxidative stress leads to IκB kinase (IKK) activation that can cause phosphorylation
of IκB, thus targeting it for polyubiquitination mediated proteasomal degradation. This results in
release and nuclear translocation of NF-κB [112]. Also, oxidative stress caused due to generation
of ROS by inflammatory cells is one of the key factors by which chronic inflammation leads to
tumorigenesis [113]. NF-κB can directly inhibit Nrf-2 at the transcriptional level [114]. NF-κB competes
with Nrf-2 for transcription co-activator CREB binding protein (CBP). Also, there is recruitment
of histone deacetylase 3 (HDAC3) by NF-κB which causes local hypo acetylation hindering Nrf-2
signaling. It was reported that physical association of the N-terminal region of p65 subunit of NF-κB
with Keap1 can inhibit Nrf-2 pathway [115]. Besides interacting with cytosolic Keap1, NF-κB also
induced nuclear translocation of Keap1. NF-κB over-expressing cells had reduced levels of HO-1 that
was stimulated by interaction of Nrf2 with antioxidant response elements confirming that activation
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of NF-κB can suppress transcriptional activity of Nrf-2. In endothelial cells, HO-1 prevents TNF-α
mediated activation of NF-κB [116]. Inhibition of NF-κB dependent transcriptional apparatus by
HO-1 has been proposed. Nuclear translocation as well as suppression of NF-κB downstream of IκB
degradation could be the site of action of HO-1. This further suggests that Nrf-2 mediated upregulation
of HO-1 is one of the centers for crosstalk between Nrf-2 and NF-κB.
NF-κB activation induced by LPS may be mitigated by several Nrf-2 activators such as SFN, CUR
and phenethyl isothiocyanate (PEITC) [117]. Additionally, SFN and PEITC could also hinder IKK/IκB
phosphorylation and nuclear translocation of p65 NF-κB subunit resulting in the inhibition of NF-κB
signaling [118]. One of the studies suggested putative crosstalk between Nrf-2 and NF-κB1 regulated
through mitogen-activated protein kinase (MAPK) cascade that may affect inflammation-linked
etiopathogenesis of cancer [119].
Two of the most critical pathways by which SFN displays its potent chemopreventive effect
in PCa are Nrf-2 activation [38–42] and NF-κB inhibition [38,39,118,120–122]. SFN induces phase II
detoxification enzymes intermediated through Nrf-2 pathway thus causing elimination of electrophilic
toxicants before they can cause any damage to the cellular machinery [123]. SFN interacts with
Keap1, the inhibitory protein for Nrf-2, through its thiol groups [124] to modify multiple domains of
Keap1 [125]. SFN can also indirectly lead to the change in conformation of Keap1 by modifying the
redox status of the cell leading to the separation of Nrf-2 from Keap1 [41]. The other mechanisms by
which SFN shows its effect on Nrf-2 include activation of phosphatidylinositol 3-kinase (PI3K), protein
kinase C (PKC) and MAPK pathways and other epigenetic modifications which lead to phosphorylation
of Nrf-2, its nuclear accumulation and finally its increased transcription and stability [40,126–128].
SFN augments Nrf-2 expression in TRAMP C1 PCa cells via epigenetic regulation [40]. The reduction
in the growth of tumor in PCa was reported to be linked with Nrf-2 signaling activation i.e., stimulation
of Nrf-2 and HO-1 proteins as well as inhibition of Keap1 protein [42].
SFN inhibits the translocation of NF-κB into the nucleus and stimulation of the expression of
proinflammatory genes in PCa [129]. SFN inhibits expression of NF-κB as well as NF-κB regulated
genes by inhibiting phosphorylation of IKK (especially IKKβ) and IκBα. It also reduces nuclear
translocation of p65 in PC-3 PCa cells [118]. Moreover, the anti-inflammatory activity of SFN was
abolished in Nrf-2 knock out macrophages signifying that antioxidant activity of SFN is related
with its anti-inflammatory action [130]. In another study, SFN suppresses TNF-α stimulated NF-κB
activation via inhibiting phosphorylation and degradation of IkB α and nuclear translocation of p65.
The suppression correlated with the inhibition of NF-κB dependent genes linked with anti-apoptosis,
cell proliferation and metastasis [120]. SFN downregulated the expression of TNF-α, inducible
nitric oxide synthase (iNOS) and cyclooxygenase (Cox)-2 induced by LPS in raw macrophages [122].
The mechanism primarily responsible for SFN action was found to be suppression of NF-κB DNA
binding and transactivation of NF-κB regulated genes apparently by modulating intracellular redox
conditions. Similarly, anti-inflammatory effects of CUR and phenethyl isothiocyanate (PEITC) were
reported to reduce with Nrf-2 knockout [45].
4.2. Crosstalk between NF-κB and AR Signaling
Crosstalk between androgen and pro-inflammatory signaling has been shown to remodel AR
and NF-κB cistrome that reprograms transcriptome of PCa cell in a way that leads to the progression
of PCa [131]. There is close proximity as well as overlap between binding sites for NF-κB and
androgen receptor response elements suggesting that cooperative NF-κB and AR binding can lead to
transcriptional regulation of PSA [82]. NF-κB thus can activate the expression of PSA and is found to
be elevated in androgen independent PCa compared to androgen dependent PCa.
NF-κB significantly upregulates the mRNA as well as protein levels of AR, transactivation of
AR, cell proliferation as well as PSA levels in the serum by binding directly to the AR promoter and
activating it [73]. This was corroborated by using NF-KB inhibitors which downregulated all the
above parameters in vitro. Moreover, NF-κB inhibitors also showed anti-cancer activity in androgen
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deprivation resistant PCa xenografts. A strong correlation was observed in the expression of AR and
NF-κB in human PCa suggesting that NF-κB inhibitors can have a therapeutic potential in PCa as they
can regulate the expression of AR. The compound, 3,3-diindolylmethane (DIM) was shown to inhibit
cellular proliferation and induce apoptosis in androgen dependent LNCaP and androgen independent
C4-2B PCa cell lines by disrupting the potential crosstalk between Akt, NF-κB and AR through
significant inhibition of NF-κB DNA binding activity, Akt activation as well as AR phosphorylation
and the expression of AR and PSA [132]. DIM further suppressed nuclear translocation of AR resulting
in the downregulation of AR target genes. AR activation as well as elevated expression of PSA by IL-4
was repressed by IκBα. Further, IL-4 stimulated NF-κB activation and nuclear translocation was shown
to be blocked by PI3K/Akt inhibitor [133]. This study showed that crosstalk between IL-4, Akt and
NF-κB signaling pathways can play a vital role in the transition of androgen dependent PCa to CRPC
by activating AR signaling. The resistance of CRPC cells to antiandrogens was overcome by targeting
NF-κB signaling using artesunate [76]. The combination was able to reduce NF-κB signaling as well
as decrease the expression of AR and AR-V7 through ubiquitin proteasomal pathway. This study
highlighted that the combination of NF-κB inhibitors and AR antagonists may potentiate the clinical
efficacy in CRPC patients. The enhanced PCa severity may activate NF-κB and AR-V7 [134]. The forced
activation of NF-κB could induce AR-V7 expression in human prostate cells leading to resistance to
5α-reductase inhibitor (5ARI) treatment. This signified a possible mechanism by which patients can
develop resistance to 5ARI. One of the studies showed that secretory proteins from neuroendocrine
cells were able to stimulate NF-κB signaling in androgen dependent PCa cells that increased active
AR levels [72]. Inhibition of AR activation was achieved by inhibiting NF-κB signaling in vitro.
Furthermore, absence of IκBα inhibitor resulted in constant activation of NF-κB signaling in vivo
which prevented regression of the prostate after castration. High nuclear levels of AR were sustained
along with the maintenance of differentiated function and renewed proliferation of the epithelium.
This study showed that activation of NF-κB pathway by neuroendocrine secretory proteins could
sustain androgen independent growth of PCa by regulating AR. One of the other reports studying
inflammation in benign prostate hyperplasia patients showed that patients having potent immune
inflammation had larger volumes of prostate, increased AR and serum PSA levels [135]. ADT in
mice activates an inflammatory response by the dying PCa cells causing the permeation of B and T
cells [136]. The B cells produce lymphotoxin and other factors that enhance IKKα and Stat3 signaling
critical for the androgen independent survival of PCa cells. These studies demonstrate the importance
of targeting NF-κB signaling in PCa to abrogate AR signaling.
4.3. Crosstalk between Nrf-2 and AR Signaling
Oxidative stress contributes to the initiation, progression and transition of PCa to CRPC by
activating AR signaling [137]. Thus reducing oxidative stress by the use of therapeutic agents that
can activate Nrf-2 can prevent the conversion of PCa to CRPC. Nrf-2 has been shown to decrease
transactivation of AR by inducing the nuclear accumulation of p120-Nrf1 [138]. In this study,
the overexpression of Nrf-2 was shown to significantly suppress dihydrotestosterone (DHT) induced
activity of AR. This AR downregulation effect of Nrf-2 overexpression was seen both under basal as
well as DHT induced conditions in the androgen dependent PCa cell line (LNCaP) but only under DHT
induced conditions in androgen independent PCa cell line (C4-2B). Moreover, Nrf-2 overexpression
was also able to decrease nuclear levels of AR under DHT stimulated conditions in LNCaP cells but
not in C4-2B cells. This study thus demonstrated a unique mechanism by which oxidative stress
stimulated transcription factors are used by PCa cells to enhance AR function notwithstanding low
androgen levels during ADT. The balance between Nrf-1 and Nrf-2 is very critical in regulating activity
of AR as well as oxidative stress in PCa cells [139].
We recently showed that bardoxolone methyl (BM) which is a potent Nrf-2 inducer can increase
the efficacy of enzalutamide in an enzalutamide-resistant PCa cell line (CWR22Rv1) by degrading
both AR-FL as well as AR-V7 further underscoring the AR suppressive function of Nrf-2 [109].
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This corroborates the fact that AR downregulation and Nrf-2 activation are the major pathways
responsible for the anticancer efficacy of phytochemicals like SFN [38–42] and CUR [43–47] in PCa.
SFN has been shown to augment expression of Nrf2 in mouse TRAMP C1 PCa cells [40] and cause
transcriptional repression [140] as well as destabilization of AR in PCa cells [141]. We also showed
in two of our recent studies that SFN can degrade both AR-FL and AR-V7 in PCa cell lines and thus
increase the efficacy of antiandrogens in both androgen dependent as well as androgen independent
PCa cell lines [108,109]. Similar to SFN, CUR was reported to reactivate Nrf-2 signaling in mouse
TRAMP C1 PCa cells through epigenetic regulation [46] and downregulate gene expression and
activation of AR in both androgen dependent as well as androgen independent PCa cell lines [142,143].
CUR analog Ca27 downregulates AR in PCa cells through oxidative stress mediated mechanism as
well as activate Nrf-2 and Nrf-2 regulated genes [144]. Thus, activation of Nrf-2 pathway can lead to
the downregulation of AR signaling in PCa.
5. Conclusions
Oxidative stress and inflammation are the key players involved in the initiation and progression
of PCa because of their potential to modulate AR signaling. Thus the integrated signaling network
involving Nrf-2, NF-κB and AR plays a very critical role both in the development and therapy of PCa
(Figure 1). Therefore, there is a critical need for a therapy that can simultaneously target oxidative stress,
inflammation and AR signaling in PCa. Phytochemicals, the chemical compounds produced by plants,
can exert significant biological effects on human cells. They may have promising anti-cancer effect due
to their ability to modulate a number of molecular signaling pathways involved in tumorigenesis [145].
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Figure 2. ultiple effects of SF /CUR: SFN/CUR shows its anti-cancer effect in PCa by activation
of Nrf-2 signaling and inhibition of NF-κB as well as AR signaling. As these three path ays are
interlinked ith each other, it leads to the upregulation of antioxidant proteins and downregulation of
inflammatory proteins eventually resulting in the overall suppression of AR signaling and PCa growth.
Numerous studies have shown the anti-cancer efficacy of SFN, an isothiocyanate derived from
broccoli in various different kinds of cancers [38,39,121,146,147]. Similarly, curcumin has been shown
to have promising anti-cancer effects [44,46,142–144]. Due to their ability to concurrently target
oxidative stress, inflammation and AR signaling in PCa, SFN and CUR may be very beneficial
and promising in treating PCa, at the initiation as well as at the later stage (Figure 2). However,
low bioavailability of phytochemicals is a major challenge. To overcome this, liposomal and other
nanoformulations are being currently used to enhance their solubility in water and thus their
Cancers 2018, 10, 352 9 of 16
bioavailability [148–151]. As phytochemicals are derived from natural sources, they are generally
considered to be safe. However, they can show toxic effect at certain concentrations and situations
like drug-drug interaction [152]. These limitations can hinder the clinical and chemopreventive
applications of phytochemicals. Therefore, a comprehensive knowledge of the phytochemicals and
their pharmacological effects is very critical for their transition from bench side to bedside (Figure 2).
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